UNIPROT:P61278 - FACTA Search

Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Target Concepts:

Query: UNIPROT:P61278 (somatostatin)
22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Regulation of preprosomatostatin mRNA and tyrosine hydroxylase mRNA were examined in sympathetic neurons of the rat superior cervical ganglion (SCG). Surgical denervation of the adult SCG increased ganglion levels of preprosomatostatin (SS) mRNA more than 11-fold, and levels of the mRNA remained elevated 14 days after surgery. By contrast, denervation decreased levels of tyrosine hydroxylase (TH) mRNA. Potassium- or veratridine-induced membrane depolarization of cultured neonatal sympathetic neurons decreased levels of SS mRNA but elevated levels of TH mRNA. Sodium channel blockade with tetrodotoxin prevented the effects of veratridine on SS and TH mRNAs. In toto these observations suggest that transsynaptic nerve impulse activity and sympathetic neuron membrane depolarization decrease SS synthesis but increase TH synthesis at the mRNA level. Thus nerve impulse activity may alter the relative levels of different transmitters co-expressed in the same neuronal population by inhibiting levels of some species of mRNA while simultaneously stimulating levels of others.
...
PMID:Differences in the effects of membrane depolarization on levels of preprosomatostatin mRNA and tyrosine hydroxylase mRNA in rat sympathetic neurons in vivo and in culture. 256 23

Somatostatin, morphine, and opioids inhibit transmitter release at intact neuromuscular junctions between ciliary ganglion neurons and the choroidal smooth muscle of the chick eye. Somatostatin and morphine, however, have no effect on release from terminals on the striated muscle target of the ciliary ganglion, the iris. In neuronal terminals of both the choroid and the iris, a high-affinity Na+-dependent choline uptake-mediated ACh synthesis is present at hatching. Both tissues exhibit a basal release of 3H-ACh which is potentiated severalfold during a 5 minute incubation in 55 mM K+ Tyrodes. Fifty percent of the basal release and 100% of the stimulated release are Ca2+ dependent and probably mediated through N-like voltage-dependent Ca2+ channels. Co-incubation of the choroid with 10 microM morphine sulfate blocks approximately 90% of the stimulated release. The same effect is seen with 100 nM somatostatin, 10 microM dynorphin, and 100 microM met-enkephalin arginine phenylalanine. Preincubation of the excised choroid with pertussis toxin (200 ng/ml) reverses the inhibitory effects of both morphine and somatostatin. In contrast, 3H-ACh release from terminals in the striated iris is not affected by either morphine or somatostatin at micromolar levels. These results suggest that both opiate and somatostatin receptors are present in the choroid target and that they may act through a final common pathway to modulate ACh release via G proteins. Second messengers such as cyclic AMP or diacylglycerol do not appear to mediate these effects; neither increasing cAMP levels in terminals nor activation of protein kinase C affects evoked release or its inhibition by morphine or other neuromodulators. It is unclear whether endogenous neuromodulation occurs in this system, although somatostatin-like immunoreactivity can be demonstrated in terminals of choroid neurons.
...
PMID:Opiate and peptide inhibition of transmitter release in parasympathetic nerve terminals. 256 61

Prolonged (12-day) sodium restriction increased basal plasma concentration of aldosterone and provoked a notable hypertrophy of the zona glomerulosa and its cells in rats. A 7-day infusion of dopamine or somatostatin, at a rate which was found to exert a maximum inhibition of aldosterone secretion in 12 h, only partially reversed the effects of sodium deprivation. However, the combined administration of these two molecules not only completely annulled the effects of sodium restriction, but also lowered plasma aldosterone concentration and the volumes of the zona glomerulosa and its cells below the values found in rats fed a normal diet. These findings confirm the contention that dopamine and somatostatin are both involved in the negative control of the growth and steroidogenic capacity of the rat zona glomerulosa, and suggest that different mechanisms underlie the antiadrenoglomerulotrophic action of these molecules.
...
PMID:Further studies on the involvement of dopamine and somatostatin in the inhibitory control of the growth and steroidogenic capacity of rat adrenal zona glomerulosa. 256 77

A high molecular weight somatostatin-immunoreactive polypeptide, presumably prosomatostatin, was purified from rat brain and characterized. Purification steps included extraction with 2 M acetic acid, precipitation of contaminating proteins at pH 6.5, Sephadex G-50 chromatography, immunoaffinity chromatography, and HPLC steps (size exclusion and reversed-phase HPLC). The protein was purified more than 30,000-fold. It is heat stable. Sodium dodecyl sulfate-gel electrophoresis and immunoblotting revealed one major immunoreactive band of approximately 13,000 molecular weight which roughly corresponds to the size of prosomatostatin as derived from its DNA sequence. Isoelectric focusing and two-dimensional sodium dodecyl sulfate-gel electrophoresis gave a single immunoreactive spot at a pI of 5.4. The polypeptide did not bind to concanavalin A or to wheat germ lectin columns, suggesting lack of N-glycosylation in the molecule. Regional distribution of prosomatostatin varied between 6%, 10%, and 18% of total immunoreactivity in the brainstem, cortical areas, and striatum, respectively.
...
PMID:Purification and characterization of prosomatostatin from rat brain. 256 2

Previous studies have shown that somatostatin receptors on AtT-20 and GH3 pituitary tumor cells show relative preference for binding somatostatin-28 (S-28) and somatostatin-14 (S-14), respectively. Here we have attempted to determine whether this selectivity can be explained by molecular heterogeneity of the receptor. Cells were incubated with [125I-Tyr11]S-14, [125I-Leu8-D-Trp22,Tyr25]S-28, and [125I-Tyr3]SMS, and the bound ligand was chemically cross-linked with bis-[2-succinimido-oxycarbonyloxy)ethyl]sulfone, disuccinimidyl suberate, or dithiobis (succinimidyl propionate). The solubilized cross-linked material was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by autoradiography. [125I-Tyr11]S-14 labeled three specific receptor proteins of 57K, 42K, and 27K mol wt in AtT-20 cells. The relative proportions of the protein bands were unaltered by the use of whole cells or cell membranes or by the inclusion of dithiothreitol or antiproteolytic agents. With both [125I-Tyr11]S-14 and [125I-LTT]S-28, the 57K protein constituted the major labeled component, representing 70-75% of the total cross-linked proteins. Labeling of the three protein species by [125I-Tyr11]S-14 and [125I-LTT]S-28 was inhibited by both S-14 and S-28 in a dose-dependent manner. S-28 was 10-20 times more potent than S-14 for inhibiting the labeling by both ligands of the principal receptor species of 57K. By contrast, when a radioiodinated derivative of the octapeptide analog octreotide ([125I-Tyr3]SMS) was used as ligand, the 27K protein was preferentially labeled, whereas the 57K and 42K bands were detected only as minor components. Labeling of GH3 cells with [125I-Tyr11]S-14 and [125I-LTT]S-28 revealed three cross-linked proteins of 57K, 42K, and 27K mol wt similar to those observed in AtT-20 cells. However, in this cell line the 27K protein, not the 57K species, was the dominant component identified with these two ligands, comprising 40-50% of the total cross-linked proteins. These results suggest that there are three somatostatin receptor proteins of 57K, 42K, and 27K in pituitary cells. In AtT-20 cells, the 57K protein constitutes the major receptor protein labeled by [125I-Tyr11]S-14 and [125I-LTT]S-28, whereas the 27K protein is the major species labeled by [125I-Tyr3]SMS. The 27K, not the 57K, moiety is the principal receptor form in GH3 cells. Such ligand- and tissue-selective binding by the somatostatin receptor provides strong evidence for receptor molecular heterogeneity.
...
PMID:Evidence for multiple protein constituents of the somatostatin receptor in pituitary tumor cells: affinity cross-linking and molecular characterization. 256 26

L-Glutamate, N-methyl-D-aspartic acid (NMDA), quisqualate, and kainate were found to increase endogenous somatostatin release from primary cultures of rat cortical neurons in a dose-dependent manner. The rank order of potency calculated from the dose-response curves was quisqualate greater than glutamate = NMDA greater than kainate, with EC50 values of 0.4, 20, and 40 microM, respectively. Alanine, glutamine, and glycine did not modify the release of somatostatin. The stimulation of somatostatin release elicited by L-glutamate was Ca2+ dependent, was decreased by Mg2+, and was blocked by DL-amino-5-phosphonovaleric acid (APV) and thienylphencyclidine (TCP), two specific antagonists of NMDA receptors. The NMDA stimulatory effect was strongly inhibited by APV in a competitive manner (IC50 = 50 microM) and by TCP in a noncompetitive manner (IC50 = 90 nM). The release of somatostatin induced by the excitatory amino acid agonists was not blocked by tetrodotoxin (1 microM), a result suggesting that tetrodotoxin-sensitive, sodium-dependent action potentials are not involved in the effect. Somatostatin release in response to NMDA was potentiated by glycine, but the inhibitory strychnine-sensitive glycine receptor did not appear to be involved. Our data suggest that glutamate exerts its stimulatory action on somatostatin release essentially through an NMDA receptor subtype.
...
PMID:Actions of excitatory amino acids on somatostatin release from cortical neurons in primary cultures. 257 Jan 26

The physical properties of brain and pituitary somatostatin receptors were characterized using photocrosslinking techniques. Somatostatin receptors in rat corpus striatum and anterior pituitary membranes were covalently bound to the non-reducible somatostatin analog, [125I]CGP 23996, using the crosslinking agent n-hydroxysuccinimidyl-4-azidobenzoate and ultraviolet light. In striatal membranes, a protein of 60,000 mol. wt was labeled by [125I]CGP 23996. The binding was potently inhibited by somatostatin analogs but not by other biologically active peptides. The labeling of the 60,000 mol. wt protein by [125I]CGP 23996 was diminished by guanine triphosphate gamma thiol, which is consistent with the labeling of a somatostatin receptor coupled to guanine triphosphate binding proteins. The migration of the [125I]CGP 23996 labeled 60,000 mol. wt protein in native sodium dodecyl sulfate-gels was not affected by the reducing agent dithiothreitol, indicating that there is a general lack of disulfide bridges in the striatal somatostatin receptor. The striatal somatostatin receptor was solubilized with the detergent 3-[(3-cholamidopropyl)-dimethylaminoio]-1-propanesulfonate and specifically bound to the lectin wheat germ agglutinin, suggesting that the striatal somatostatin receptor is a glycoprotein. [125I]CGP 23996 also labeled a 60,000 mol. wt protein in anterior pituitary membranes. The characteristics of [125I]CGP 23996 binding to anterior pituitary membranes were consistent with the labeling of a somatostatin receptor. Interestingly, a comparison of the [125I]CGP 23996 labeled material from striatal and anterior pituitary membranes by two-dimensional polyacrylamide gel electrophoresis revealed the presence of several striatal somatostatin receptors of varying charge (pI values between 6 and 6.5) but only a single pituitary receptor. These findings indicate that physical differences may exist between subtypes of somatostatin receptors.
...
PMID:Biochemical properties of brain somatostatin receptors. 257 Mar 75

1. Somatotroph cells were obtained from pituitaries of adult male rats by dissociation, separation and enrichment on a continuous gradient of bovine serum albumin at unit gravity. They were kept in culture for 7-15 days before electrophysiological experiments. 2. Immunofluorescent staining of the resulting gradient fractions (numbered F2 to F9) indicated that the majority of somatotrophs (75-85%) were located in the heavy fractions (F8 and F9). However, a small percentage (15-20%) of cells in these fractions were identified as lactotrophs. 3. Perifusion experiments indicated that on the one hand release of growth hormone from somatotroph-enriched fractions was stable at the level of 6 ng (2 min)-1 (10(6) cells)-1 and was markedly inhibited by somatostatin (1.9 ng (2 min)-1 (10(6) cells)-1) but not by dopamine. On the other hand, in the same cell preparations, basal prolactin release (1.6 ng (2 min)-1 (10(6) cells)-1) was significantly reduced by dopamine (0.08 ng (2 min)-1 (10(6) cells)-1) but remained unchanged by somatostatin treatment. 4. The inhibitory effect of somatostatin on growth hormone release was dose dependent. This effect was not abolished by tetraethylammonium (40 mM) or 4-aminopyridine (5 mM), but somatostatin decreased high-potassium-induced release. 5. In all the cells recorded (n = 187), 14% (n = 26) displayed a low resting potential (less than -30 mV) and poor membrane resistance (less than 50 M omega). The recording was unstable and resting potentials decreased regularly to 0 mV in less than 5 min. The other 86% of the cells displayed resting potentials varying from -45 to -65 mV and had a membrane resistance of more than 150 M omega. Only cells which displayed these membrane characteristics showed clear responses to somatostatin or dopamine, and were therefore chosen for experiments. 6. In all the cells selected for the experiments (n = 161), 78% (n = 126) showed either triggered or spontaneous action potentials. The action potentials remained insensitive to sodium-free bath solution, but were reversibly blocked by the calcium channel blockers cobalt (5 mM) or nickel (5 mM). 7. When the cells were at resting potential, somatostatin induced a hyperpolarizing response associated with a decrease of membrane resistance. During this response, spontaneous or triggered action potentials were inhibited. The hyperpolarizing response induced by somatostatin was dose-dependent.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Electrophysiological responses to somatostatin of rat hypophysial cells in somatotroph-enriched primary cultures. 257 Aug 71

The present communication examines the influence of somatostatin (SRIF14) on basal and thyrotropin-releasing hormone (TRH)- or growth hormone-releasing factor (GRF)-induced GH secretion in young (6 week old) and adult male chickens. Studies were performed in sodium pentobarbitone-anesthetized chickens where basal plasma concentrations of GH are low and both TRH and GRF consistently stimulate GH release. In both young and adult chickens, basal GH secretion was reduced by SRIF14 infusion (3 micrograms/kg/min). Similarly, in adult and young birds, the GH secretory response to a challenge with a GRF bolus (10 micrograms/kg) was inhibited by the concomitant intravenous infusion of SRIF14 (0.3 or 3.0 micrograms/kg/min). In adult chickens, the GH response to TRH (10 micrograms/kg) was suppressed (by 93%) by SRIF14 infusion (3 micrograms/kg/min) and tended to be inhibited (by 29%) by a lower dose of SRIF14 (0.3 micrograms/kg/min). In contrast, in young chicks, GH release following TRH challenge (either 1 or 10 micrograms/kg) was only partially inhibited by SRIF14 infusion (3 micrograms/kg/min). The response to a TRH challenge (10 micrograms/kg) was unaffected by the low dosage of SRIF14 infusion (0.3 micrograms/kg/min). It is concluded that SRIF14 inhibits both GRF- and TRH-stimulated GH release in young and adult chickens.
...
PMID:Somatostatin inhibition of thyrotropin-releasing hormone- and growth hormone-releasing factor-induced growth hormone secretion in young and adult anesthetized chickens. 257 6

Activation of beta-adrenergic and somatostatin receptors increases and attenuates, respectively, cAMP. We have determined, however, that in enteric endocrine cells beta-adrenergic and somatostatin receptors also regulate Na-H exchange activity, independent of their effects on cAMP. In cells loaded with a pH-sensitive dye, epinephrine, acting at a beta 2-adrenergic receptor induced an alkalinization while somatostatin caused an acidification of intracellular pH (pHi). These pHi changes were dependent on extracellular Na+ and inhibited by amiloride. Forskolin, dibutyryl-cAMP and 8-bromo-cAMP, however, had no effect on pHi. Cholera toxin, while decreasing the EC50 for epinephrine-stimulated increases in cAMP, had no effect on epinephrine-induced alkalinization, suggesting receptor coupling to Na-H exchange was not mediated by a cholera toxin-sensitive stimulatory GTP-binding protein (Gs). Additionally, epinephrine stimulated Na-H exchange in cyc- variants of S49 lymphoma cells, which lack a fundamental Gs. In the presence of pertussis toxin, somatostatin attenuation of cAMP was completely reversed; however, somatostatin inhibition of Na-H exchange was not affected. We suggest that beta-adrenergic and somatostatin receptors regulate Na-H exchange independent of changes in cAMP and possibly independent of GTP-binding proteins previously described as being coupled to these receptors.
...
PMID:Beta-adrenergic and somatostatin receptors regulate Na-H exchange independent of cAMP. 257 75

<< Previous 1 2 3 4 5 6 7 8 9 10